ライフサイエンスコーパス: post-menopausal

1 premenopausal (age < 50 years) and 357 were post- menopausal.

2 emale mice and pre- (42.3 +/- 0.5 years) and post-menopausal (61.9 +/- 0.9 years) women.

3 All women were post-menopausal and of European ancestry.

4 individuals with the highest Abeta load were post-menopausal and peri-menopausal women with ATP/PCr r

5 s a paucity of data regarding the effects of post-menopausal-associated estrogen loss on cellular fun

6 the 20 symptoms (abnormal mole, breast lump, post-menopausal bleeding, rectal bleeding, lower urinary

7 inhibition suggesting their use in pre- and post-menopausal breast cancer patients, respectively.

8 s (WBFFM) are both associated with increased post-menopausal breast cancer risk, and colorectal cance

9 s on the response of Estrogen Receptor (ER)+ post-menopausal breast cancer tumors to aromatase inhibi

10 ose-response associations in endometrial and post-menopausal breast cancer, and in degree and duratio

11 biomarkers as potential novel predictors for post-menopausal breast cancer.

12 ch five showed significant associations with post-menopausal breast cancer: plasma urea (HR = 0.95, 9

13 odds ratios (OR) <= 3] for (mostly peri- and post-menopausal) breast cancer.

14 , health-related, and demographic factors in post-menopausal, but not pre-menopausal, women, with bio

15 with ABS compared with patients with MI and post-menopausal controls (p < 0.05).

16 tly lower in patients with ABS compared with post-menopausal controls (p < 0.05).

17 ncreased in patients with ABS, compared with post-menopausal controls, following acute mental stress

18 ute mental stress in patients with MI versus post-menopausal controls.

19 ular and cortical parameters consistent with post-menopausal disease, and negative phosphorus balance

20 e biological backgrounds, including pre- and post-menopausal donors, significantly enhances the appli

21 and PR isoform expression in normal pre- and post-menopausal endometrium, well-differentiated endomet

22 d bone mass through weight-bearing exercise, post-menopausal ERT, and adequate calcium intake.

23 Post-menopausal estrogen loss alone facilitates metaboli

24 RNA-seq comparison of 85,107 pre- and 46,111 post-menopausal fallopian tube cells reveals substantial

25 r being hospitalized or diagnosed with ABS), post-menopausal female controls (n = 12), and female pat

26 y, from baseline serum/plasma samples of 191 post-menopausal female liver cancer cases (HCC n=83, ICC

27 among 2495 male participants >=60 years and post-menopausal female participants >=65 years from a ge

28 ownstream nodes for a pre-menopausal female, post-menopausal female, younger male, and older male con

29 hormone (FSH), a gonadotropin that rises in post-menopausal females, activates its receptor FSHR in

30 levels were low in the majority of males and post-menopausal females, but within normal limits for pr

31 's health, such as in oral contraception and post-menopausal hormone therapy.

32 y was a significant risk factor among women; post-menopausal hormones use was only associated with an

33 A post-menopausal hot flush consists of profuse physiologi

34 f physiological symptoms that occur during a post-menopausal hot flush.

35 High post-menopausal levels of the pituitary gonadotropin fol

36 Grandmother Hypothesis to simulate how human post-menopausal longevity could have evolved as ancestra

37 d into three groups: pre-menopausal (n = 7), post-menopausal (n = 11) and post-menopausal taking HRT

38 icrobial-dose-doxycycline (SDD) treatment of post-menopausal osteopenic women significantly reduced p

39 128 post-menopausal osteopenic women with chronic periodonti

40 above both eroded and formative surfaces in post-menopausal osteoporosis patients, and that this abs

41 These include post-menopausal osteoporosis, spinal cord injury, rheuma

42 sing humanized IL-27 toward the treatment of post-menopausal osteoporosis.

43 vaginal infections, fertility, pregnancy and post-menopausal osteoporosis.

44 remodeling in a widespread disease, such as post-menopausal osteoporosis.

45 s are therapeutic agents in the treatment of post-menopausal osteoporosis.

46 lso improved bone strength in a rat model of post-menopausal osteoporosis.

47 reatment of osteopenic conditions, including post-menopausal osteoporosis.

48 ogen deficiency, replicating many aspects of post-menopausal osteoporosis.

49 3 mRNA was significantly correlated with the post-menopausal (p = 0.003) status and positive lymph no

50 usted p-value = 0.015) and more likely to be post-menopausal (p-value = 0.004; BH-adjusted p-value =

51 nificantly shorter survival, specifically in post-menopausal patients with advanced and terminal stag

52 ular subtype, a subset of genes expressed in post-menopausal secretory epithelial cells show enrichme

53 age and extended to the other regions at the post-menopausal stage (p = 0.001).

54 e predict skin hydration, subject's age, pre/post-menopausal status and smoking status from the leg s

55 When matched the participants by age, post-menopausal status was still associated with a highe

56 Increasing age and post-menopausal status were associated with the presence

57 Post-menopausal stratum corneum contained lower levels o

58 pausal (n = 7), post-menopausal (n = 11) and post-menopausal taking HRT (n = 10).

59 gulates metabolic physiology, highlighted by post-menopausal temperature dysregulation (hot flashes),

60 (+/-10 years), 161 women, of whom, 104 were post-menopausal) underwent tau and beta-amyloid (Abeta)-

61 , and May 31, 2024, and were not pregnant or post menopausal were included.

62 ale patients aged 18 years or older who were post-menopausal with histologically or cytologically con

63 with cardiovascular disease (CVD) risk among post-menopausal women (n = 2479) using data from the Kor

64 n independently influenced oral bone loss in post-menopausal women aged <70 years.

65 Between 2001 and 2005, a total of 202 638 post-menopausal women aged 50-74 years were randomly ass

66 th Initiative Hormone Trials enrolled 27,347 post-menopausal women ages 50 to 79 years.

67 (FGF21) levels and pericardial fat volume in post-menopausal women and high cardiovascular disease (C

68 cardiomyopathy that occurs predominantly in post-menopausal women and may be triggered by acute ment

69 tion is critical for designing therapies for post-menopausal women and others with dementia.

70 n was more pronounced in peri-menopausal and post-menopausal women carrying apolipoprotein E-4 (APOE-

71 onary heart disease (CHD) risk prediction in post-menopausal women compared with assessment using tra

72 Formula: see text] 1.7 k features in 104,313 post-menopausal women from the UK Biobank.

73 Participants were 84,537 post-menopausal women from the WHI (Women's Health Initi

74 Additionally, post-menopausal women had higher sphingomyelin levels, s

75 Post-menopausal women have an increased risk of developi

76 Furthermore, rising levels of LH in post-menopausal women have been implicated in the high p

77 Men and post-menopausal women have greater risk of developing co

78 noni), enhanced performances in athletes and post-menopausal women in clinical studies.

79 therapy (HRT) has been used increasingly by post-menopausal women in western countries.

80 se, risk factors for sudden cardiac death in post-menopausal women include African-American race, hig

81 Post-menopausal women more frequently have many traditio

82 ex/hormone status was grouped as: 1) men; 2) post-menopausal women not receiving hormone replacement

83 s men, with attenuated sex differences among post-menopausal women not taking hormone replacement the

84 omen but positively with HI in obese men and post-menopausal women not using hormone replacement ther

85 d risk of future systemic bone loss in these post-menopausal women not yet on anti-osteoporotic drugs

86 With the aging U.S. population, post-menopausal women now have the greatest population b

87 significant shifts in the gut microbiome of post-menopausal women on severe calorie restriction conc

88 in two measures of olfactory function in 14 post-menopausal women receiving estrogen replacement the

89 en not receiving hormonal contraceptives; 4) post-menopausal women receiving hormone replacement ther

90 ng estrogen replacement therapy (ERT) and 48 post-menopausal women receiving no such therapy.

91 therapy to prevent cardiovascular disease in post-menopausal women remains contentious.

92 ological age acceleration being lowest among post-menopausal women reporting between three and four l

93 Compared with age-matched men, post-menopausal women showed significantly higher tau-PE

94 CV complications are more severe in men and post-menopausal women than in pre-menopausal women.

95 window hypothesis, i.e., that the brains of post-menopausal women ultimately lose their ability to r

96 In a preference trial, 18 symptomatic post-menopausal women underwent a passive heat stress to

97 One hundred and twenty post-menopausal women were recruited into a 6-month rand

98 s and histological composition of the USL in post-menopausal women with and without POP at various st

99 ouble-blind, double-dummy trial, we enrolled post-menopausal women with at least two moderate or one

100 wer WID-REA in cancer-free women, but not in post-menopausal women with breast or ovarian cancer.

101 open-label study of camizestrant in pre- and post-menopausal women with estrogen receptor-positive (E

102 tase inhibitor administered after surgery to post-menopausal women with hormonally responsive breast

103 In this population of post-menopausal women with lichen sclerosus the majority

104 ted the vaginal and vulvar microbiomes of 27 post-menopausal women with lichen sclerosus.

105 rative analyses in a Chinese cohort of peri-/post-menopausal women with metagenomics/targeted metabol

106 sus the first-approved SERD, fulvestrant, in post-menopausal women with oestrogen receptor-positive,

107 One hundred twenty-eight eligible post-menopausal women with periodontitis and systemic os

108 d, double-blind, placebo-controlled trial of post-menopausal women with serum 25-hydroxyvitamin D con

109 INTERPRETATION: Among post-menopausal women with severe osteoporosis, the risk

110 rum metabolites in 21 subjects (9 men and 12 post-menopausal women) with chronic inflammation and som

111 n a preference-controlled trial involving 21 post-menopausal women, 16 weeks of supervised moderate i

112 with increased incidence of breast cancer in post-menopausal women, and with increased mortality from

113 n reduces the risk of Alzheimer's disease in post-menopausal women, beta-amyloid (Abeta) burden in an

114 ascular disease, the major cause of death in post-menopausal women, can be reduced by replacement of

115 n and -12.5 ml/yr (95% CI, -16.2 to -8.9) in post-menopausal women, compared with women menstruating

116 ssue, which are major sources of estrogen in post-menopausal women, could up-regulate hPRLR gene expr

117 was associated with decreasing HF risk among post-menopausal women, even in the absence of antecedent

118 Among post-menopausal women, higher LDL cholesterol and trigly

119 Among post-menopausal women, higher total cholesterol (aOR: 1.

120 fied potential markers for MetS screening in post-menopausal women, highlighting the need for early i

121 declined more rapidly among transitional and post-menopausal women, in particular for FVC, beyond the

122 This cross-sectional study of 1256 post-menopausal women, recruited from the Buffalo center

123 In post-menopausal women, shorter total reproductive durati

124 In hyperlipidemic post-menopausal women, statin therapy induced EAT regres

125 In post-menopausal women, the attenuation of PP amplificati

126 In post-menopausal women, the Cox model Hazard Ratios (HR)

127 In post-menopausal women, this directionality is reversed.

128 y benefits the outcome of cerebral stroke in post-menopausal women, we designed the present study to

129 cidence of HF hospitalization among healthy, post-menopausal women, whereas multivariable adjustment

130 ial novel predictors for breast cancer among post-menopausal women, with pre-specified interest in th

131 he probability of breast cancer incidence in post-menopausal women.

132 t for the early prevention of memory loss in post-menopausal women.

133 a major public health issue, particularly in post-menopausal women.

134 erine (and tail) arteries from aged mice and post-menopausal women.

135 cteria in subgingival plaque samples of 1204 post-menopausal women.

136 men and -5.2 ml/yr (95% CI, -8.3 to -2.0) in post-menopausal women.

137 rdiovascular and bone remodelling markers in post-menopausal women.

138 e risk factors for breast cancer in pre- and post-menopausal women.

139 th increased bone resorption in osteoporotic post-menopausal women.

140 ne and cerebral ischemia incidents/impact in post-menopausal women.

141 onary artery calcium (CAC) in hyperlipidemic post-menopausal women.

142 SCD) and to identify risk factors for SCD in post-menopausal women.

143 is and telangiectasias were conducted on 410 post-menopausal women.

144 m bone-resorption biomarkers in subgroups of post-menopausal women.

145 We included 26,160 healthy, post-menopausal women.

146 of ovarian hormone intervention in peri- and post-menopausal women.

147 ent heart failure (HF) hospitalization among post-menopausal women.

148 was added to predictive models using TRFs in post-menopausal women.

149 centiles of a population-based study of 3100 post-menopausal women.

150 of alveolar crestal height and tooth loss in post-menopausal women.

151 d at a lower BMI, compared to females during post-menopausal years; suggesting that another factor, o